title: Autologous stem cell transplantation as consolidation therapy for patients with peripheral T cell lymphoma in first remission: long-term outcome and risk factors analysis.
abstract: This report is a retrospective analysis of 65 patients with peripheral T cell lymphoma (PTCL), who underwent high-dose therapy and autologous hematopoietic stem cell transplantation (autoHCT) as a consolidation of first response achieved with either induction or salvage chemotherapy. We intended to determine the prognostic factors that influenced outcome after autoHCT and to define the predictive value of the scoring systems most often applied for transplant outcomes. Nineteen patients in either complete or partial remission underwent autoHCT after induction chemotherapy. Forty-six patients received second-line chemotherapy as a consolidation of partial response after induction chemotherapy (n = 34) or as a salvage therapy after primary induction failure (n = 12), and thereafter proceeded to autoHCT. Finally, the 36 patients were in complete remission, and 29 in partial remission at autoHCT. The median follow-up of survivors was 53 months (range 7-157 months). The 5-year overall survival and progression-free survival for all patients were 61.5% (95% CI 47.0-74.2%) and 59.4% (95% CI 46.1-71.5%), respectively. In multivariate analysis, bone marrow involvement at diagnosis and less than partial remission after induction chemotherapy were factors independently predictive for overall survival and progression-free survival. The prognostic index for PTCL could reliably stratify the prognosis of PTCL in this analysis.
authors.affiliation: Department of Hematology, Poznan University of Medical Sciences, Szamarzewskiego 84, 61-569, Poznan, Poland. aczyz@onet.eu
authors.forename: Anna
authors.initials: A
authors.lastname: Czyz
authors.forename: Joanna
authors.initials: J
authors.lastname: Romejko-Jarosinska
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Helbig
authors.forename: Wanda
authors.initials: W
authors.lastname: Knopinska-Posluszny
authors.forename: Lidia
authors.initials: L
authors.lastname: Poplawska
authors.forename: Beata
authors.initials: B
authors.lastname: Piatkowska-Jakubas
authors.forename: Dorota
authors.initials: D
authors.lastname: Hawrylecka
authors.forename: Barbara
authors.initials: B
authors.lastname: Nasilowska-Adamska
authors.forename: Dominik
authors.initials: D
authors.lastname: Dytfeld
authors.forename: Anna
authors.initials: A
authors.lastname: Lojko-Dankowska
authors.forename: Anna
authors.initials: A
authors.lastname: Kopinska
authors.forename: Piotr
authors.initials: P
authors.lastname: Boguradzki
authors.forename: Jan
authors.initials: J
authors.lastname: Walewski
authors.forename: Slawomira
authors.initials: S
authors.lastname: Kyrcz-Krzemien
authors.forename: Andrzej
authors.initials: A
authors.lastname: Hellmann
authors.forename: Mieczyslaw
authors.initials: M
authors.lastname: Komarnicki
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D012307:Risk Factors; D016879:Salvage Therapy; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone